PAR 2.56% 20.0¢ paradigm biopharmaceuticals limited..

where are we at at the moment ?, page-36

  1. 615 Posts.
    lightbulb Created with Sketch. 258
    So all of you can do your math if the n should be 640 patients treated / jabbed in 2023

    So $41m / 640 = $64k per patient, which is A$19.2m if they only need to treat 300 is stage 2.




 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.